Critical Limb Ischemia: Evidence‑Based Management

Overview

• Immediate revascularization is recommended for patients with critical limb ischemia (CLI) to limit tissue loss and avoid amputation; the choice between endovascular or surgical approaches should be based on arterial anatomy, availability of suitable conduit, and patient life expectancy. [1][2]3

Clinical Assessment

• Non‑healing foot ulcers, gangrene, or tissue loss identify CLI and warrant urgent evaluation. [1][2]
• An interdisciplinary team evaluation is required before any amputation decision to explore all revascularization options. [1][2]3

Immediate Medical Management

• Adequate analgesia should be provided to control ischemic rest‑pain. 4
• Empiric antibiotics are indicated when infection is present; oral agents for localized infection and intravenous therapy for extensive infection with systemic signs. 3

Arterial Imaging Strategy

• Urgent arterial imaging must be performed to delineate the vascular anatomy prior to revascularization planning. [1][2]
• Duplex ultrasound is an acceptable first‑line imaging modality for defining arterial lesions. 1
• The selection of imaging modality (CTA, MRA, catheter angiography) should consider local expertise, renal function, and urgency. [1][2]

Interdisciplinary Team Composition

• The core team should include a vascular surgeon, an interventional radiologist or cardiologist, a vascular medicine physician, a wound‑care specialist, and an infectious‑disease specialist when infection is present. [3][4]

Revascularization Decision Algorithm

Patients with life expectancy ≤ 2 years or without suitable autogenous vein

• Endovascular revascularization is the preferred initial strategy. 5
• Endovascular therapy is indicated to restore inline flow for non‑healing wounds or gangrene. [1][2]6
• The BASIL trial demonstrated equivalent amputation‑free survival between endovascular and surgical approaches at 2 years. [1][2]6

Patients with life expectancy > 2 years and available autogenous vein

• Surgical bypass is a reasonable first‑line option. [5][4]
• The BEST‑CLI trial showed lower rates of major adverse limb events or death with surgical revascularization when a single‑segment great saphenous vein was used. 3
• The BASIL trial reported a significant reduction in amputation or death after 2 years with surgical bypass. 3
• For infra‑popliteal disease, the BASIL‑2 trial found endovascular revascularization provided superior amputation‑free survival, mainly due to fewer deaths, suggesting endovascular preference in high‑risk tibial disease. 3

Endovascular Strategy Details

• Revascularize hemodynamically significant stenoses (> 75 % diameter reduction, or 50‑75 % with abnormal pressure gradients). [1][2]
• In multilevel disease presenting with rest pain alone, treat inflow lesions first; reassess and stage outflow interventions if needed. [1][2]5
• Angiosome‑directed revascularization may be considered to enhance wound healing, although supporting evidence is low‑quality and lacks randomized data. [7][8]

Surgical Strategy Details

• Bypass to popliteal or infrapopliteal arteries should be performed using autogenous vein (preferably the great saphenous vein). [7][8]4
• When suitable autogenous vein is unavailable and endovascular attempts have failed, prosthetic conduit can be used effectively for bypasses to below‑knee popliteal and tibial targets. [7][4]
• For multilevel disease, address inflow lesions first; if CLI symptoms persist, proceed to outflow bypass. 5

Contraindications to Revascularization

• Revascularization is not recommended in limbs with limited life expectancy where procedural risk outweighs benefit. 3

Wound Care and Infection Control

• Aggressive off‑loading should be instituted after revascularization to promote ulcer healing. 3
• Lower‑limb exercise training must be deferred until ulcer closure. 3
• Antibiotic therapy should be guided by tissue culture results rather than empirical selection. 3
• Individualized wound‑treatment options (e.g., antimicrobial, silver, honey‑ or iodine‑based dressings, platelet‑rich plasma, collagen, negative‑pressure therapy) may accelerate healing. 3
• Assessment for a venous component in mixed ulcers is advised, with compression therapy considered after successful revascularization. 3
• Coordination of wound‑care interventions with revascularization planning should be performed by the interdisciplinary team. [7][4]

Post‑Procedural Surveillance

After Bypass Surgery

• Autogenous‑vein bypasses require periodic clinical assessment, pulse examination, and duplex ultrasound of the entire graft (including peak systolic velocities and velocity ratios) for at least 2 years. 5
• Synthetic bypasses should be monitored with symptom review, pulse checks, and ankle‑brachial index measurements at rest and after exercise for a minimum of 2 years. 5

Adjunctive Therapies for Non‑Revascularizable CLI

• Intermittent pneumatic compression devices may be employed to improve wound healing or relieve severe rest‑pain. 4
• Prostanoids are not recommended (Class III) due to lack of demonstrated benefit. 8

Prognosis

• Without revascularization, CLI is associated with a 12‑month all‑cause mortality of approximately 22 % and a major amputation rate of about 22 %. [1][2]6

Evidence‑Based Management of Critical Limb‑Threatening Ischemia (CLTI)

Immediate Recognition and Referral

• Early identification of CLTI and urgent referral to a vascular specialist team are essential for limb salvage, defined by chronic rest pain, non‑healing ulceration, or gangrene with confirmed arterial occlusion. 9
• Revascularization must be performed without delay; each hour of postponement increases the risk of amputation and mortality. 9
• Prior to any decision for primary amputation, a multidisciplinary evaluation (vascular surgery, wound care, infectious disease, cardiology) is required to explore all revascularization options. [10][11]

Medical Management While Arranging Revascularization

• Off‑loading of mechanical stress on the affected limb is required to permit ulcer healing. 9
• Structured lower‑limb exercise programs are contraindicated in patients with CLTI and active wounds because they exacerbate tissue ischemia. 9

Revascularization Decision‑Making

• The choice between an endovascular‑first versus surgical‑first strategy should be based on three key factors: availability of a suitable autogenous vein conduit, patient life expectancy, and anatomic complexity of disease. 11
• Patients with good‑quality autogenous vein and an expected survival > 2 years:
  
  • Surgical bypass is the preferred first‑line therapy. 11
  • Bypass to popliteal or infrapopliteal targets should be constructed using autogenous vein (preferably the great saphenous vein). [9][11]
  • Pre‑operative duplex ultrasound mapping of the great saphenous vein is mandatory before selecting the revascularization approach. 11
• Patients without suitable autogenous vein or with life expectancy ≤ 2 years:
  
  • Endovascular revascularization is the preferred initial modality.
  • Endovascular procedures should aim to restore in‑line blood flow to the foot in the setting of non‑healing wounds or gangrene. [10][11]

Endovascular Technical Considerations

• Hemodynamically significant stenoses (≥ 75 % diameter reduction, or 50‑75 % with abnormal pressure gradients) should be treated.
• In multilevel disease presenting with rest pain alone, inflow lesions are treated first; outflow lesions are staged after reassessment of symptoms. [12][10]
• For non‑healing wounds or gangrene, direct in‑line flow to the foot is essential to promote healing. [10][11]
• Angiosome‑directed revascularization may be considered to improve wound outcomes, although the supporting evidence is low‑quality. 10
• In femoropopliteal lesions, drug‑eluting technologies are recommended as the first‑choice treatment. 9

Surgical Technical Considerations

• In multilevel arterial disease, inflow obstructions must be eliminated before addressing downstream lesions. 9
• When both inflow and outflow disease coexist, the inflow lesion is treated first; if CLTI symptoms persist after successful inflow revascularization, an outflow bypass is performed. 12
• Infra‑inguinal bypass is appropriate for patients with adequate autologous vein and low operative risk (peri‑operative mortality < 5 % and expected 2‑year survival > 50 %). 9

Post‑Revascularization Management

• Structured, regular follow‑up is mandatory to evaluate clinical status, hemodynamics, limb symptoms, treatment adherence, and cardiovascular risk‑factor control. [9][11]

Situations Where Revascularization Is Not Indicated

• Revascularization is not recommended solely to prevent progression to CLTI in patients with asymptomatic peripheral artery disease. 9
• Primary amputation should be considered for patients with extensive weight‑bearing foot necrosis, uncorrectable joint contracture, severe limb paresis, refractory ischemic rest pain, systemic infection, or markedly limited life expectancy. 12
• Revascularization should not be performed based only on a low ankle‑brachial index (< 0.4) in the absence of clinical CLTI symptoms. 12

Interdisciplinary Care and Pitfalls

• An interdisciplinary team approach—including wound‑care specialists, infection control, and cardiovascular risk‑factor management—is essential for successful revascularization outcomes. [9][11]